ONCOS-102 is a serotype 5 adenovirus that features a chimeric capsid for enhanced gene delivery to cancer cells and a 24 bp deletion in Rb binding site of E1A for cancer cell restricted replication, and is armed with GM-CSF, a potent inducer of antitumor immunity (6). Here, CSF2 is linked to cancer.